OCT 17, 2013 3:00 PM PDT

From Genomic Questions to Clinical Answers in Cancer

C.E. Credits: CE
Speaker
  • Associate Professor of Pediatrics, Director, Pediatric Familial Cancer Clinic, University of Chicago
    Biography
      Kenan Onel, MD, PhD is an Associate Professor of Pediatrics in the Section of Hematology/Oncology, and Director of the Pediatric Familial Cancer Clinic at The University of Chicago. After receiving his undergraduate degree as well as an MA in modern European history at Yale, Dr Onel completed both an MD and a PhD in molecular biology as part of the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD program. Dr Onel then trained as a pediatrician at the Childrens Hospital of New York, and as a pediatric oncologist at the Memorial Sloan-Kettering Cancer Center. Dr Onels interest in the genetic basis of cancer developed while caring for children with cancer at Memorial Sloan-Kettering, and so, he completed a post-doctoral fellowship in cancer genetics at the Rockefeller University. As a physician/scientist, the goal of Dr Onels research is to understand the genetic contribution to cancer risk and response to therapy using genomic platforms and systems biology strategies. He has been a faculty member at The University of Chicago since 2004.

    Abstract

    Although genome-wide association studies (GWAS) have identified many single nucleotide polymorphisms (SNPs) associated with cancer, the contribution to risk of these variants is small, rendering them of little use clinically. Whereas GWAS focus on main effects, complex diseases are also influenced by many environmental factors that may affect the association between SNPs and disease. We hypothesized that a variant identified by GWAS to have a small effect in the general population may actually exert a large effect in a subset of individuals sharing a common environmental context. To test this, we performed GWAS of two therapy-induced cancers: radiation therapy-induced second cancers after Hodgkin lymphoma, and therapy-related acute myeloid leukemia. We found that common variants can have large effects in the context of specific etiological exposures. Thus, genomic studies incorporating exposures may reveal patient subsets for whom specific SNPs contribute meaningfully to disease. In the future, a major challenge will be to design genetic studies taking advantage of exposures shared by cases and controls when the contribution to disease of the exposure is less obvious than for therapy-induced cancers. Learning objectives: 1. To understand the implications of cancer as a complex disease for studies investigating genetic susceptibilities to cancer. 2. To understand the strengths and limitations of genome-wide association studies (GWAS). 3. To understand the role of PRDM1 in defending against radiation-induced second cancers.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 03, 2020 4:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources
    Attendees
    • See more